English | Français
English | Français
We have built our approach around a simple but powerful idea: harness the regenerative and anti-inflammatory potential of stem cells through an acellular, industrially viable therapeutic model.
Through a proprietary, end-to-end approach leveraging induced pluripotent stem cell (iPS) technology, directed differentiation, and acellular secretome production, we enable the development of safe, consistent, and scalable regenerative biologics.
Stem cells exert most of their therapeutic effects through the bioactive signals they release, collectively referred to as the secretome.
Rather than delivering cells, iC BIOSOLUTIONS focuses on isolating and standardizing these paracrine factors, which drive immunomodulation, tissue repair, and inflammatory control.
This shift from cell-based administration to secretome-based therapeutics defines a new therapeutic paradigm in regenerative medicine.
To support the reliable development of secretome-based therapeutics, iC BIOSOLUTIONS has established an approach based on renewable, well-characterized producer cell lines derived from iPS technology and organized into structured cell banks.
Our stable and renewable stem cell banks enable:
All production originates from well-defined, GMP-compliant cell banks, providing a reliable and scalable starting material for secretome manufacturing.
Our approach is designed to support clinical and industrial development from the outset.
Consistent biological activity
Controlled differentiation and production conditions ensure stable, well-defined secretome profiles and reproducible therapeutic potency
Safety by design
A donor-independent, cell-free product minimizes contamination risks and immunogenic concerns
Adapted to clinical use
A shelf-stable, acellular formulation enables simplified storage, transport, and clinical administration
Scalable manufacturing
Standardized processes and GMP-aligned production support large-scale manufacturing while maintaining defined quality attributes
The biological mechanisms targeted by secretome-based therapeutics (immunomodulation, tissue repair, and inflammatory control) are highly conserved across mammalian species.
Combined with an end-to-end controlled development framework, this makes the iC BIOSOLUTIONS platform intrinsically translatable across species and indications.
Building on this foundation, the iC BIOSOLUTIONS approach supports the development of multiple dedicated secretome-based products, each tailored to specific indications, species, and regulatory pathways.
The lead product candidate ICB001 represents the first clinical application of this approach in veterinary medicine and serves as an initial validation of its therapeutic potential.